Halia Therapeutics
Overview
Halia Therapeutics is a clinical-stage biopharmaceutical company specializing in the research and development of treatments for inflammatory and neurodegenerative diseases. Founded in 2017 by David J. Bearss and Jared Bearss, the company is headquartered in Lehi, Utah. Halia Therapeutics has raised significant capital, including a $30 million Series C financing round in January 2024, to support its pioneering work on novel therapeutic candidates targeting the NEK7 and LRRK2 proteins.
Recent Developments
- October 2024: Halia Therapeutics announced its participation in the Global Health Exhibition 2024 in Riyadh, Saudi Arabia, showcasing its LRRK2 and NEK7 inhibitors for Alzheimer's disease and obesity.
- September 2024: The company presented new clinical trial data for its lead drug candidate HT-6184 at the 6th Inflammasome Therapeutics Summit, highlighting its impact on inflammatory and pain responses post-surgery.
- August 2024: Dr. David Bearss, CEO, was recognized in the 2024 PharmaVoice 100 list for his leadership in the life sciences industry.
- July 2024: A collaboration with Biolexis Therapeutics successfully identified a novel candidate targeting neuroinflammation.
- May 2024: Announced the initiation of a Phase 1 clinical trial for a new Alzheimer's treatment, HT-4253.
- January 2024: Completed a $30 million Series C funding to advance clinical trials and drug developments, focusing on neuroinflammatory disorders.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2017 |
| Headquarters | Lehi, Utah, USA |
| Founders | David J. Bearss, Jared Bearss |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Todd Pedersen, among others. |
| Industry | Biopharmaceuticals |
| Number of Employees | Approximately 18 |
Early History
Halia Therapeutics was founded in 2017, drawing from the rich biotechnological expertise available in Utah. The company's formation was inspired by genetic research conducted by co-founder John "Keoni" Kauwe, who discovered a family in Utah resistant to Alzheimer's despite genetic predispositions. This breakthrough catalyzed the development of therapeutics focusing on chronic inflammation pathways. From its inception, Halia has aimed to create therapies that target the root causes of neurodegenerative and inflammatory diseases.
Company Profile and Achievements
Halia Therapeutics has positioned itself as an innovator in targeting complex pathways involved in chronic inflammation and neurodegeneration.
- HT-6184 Development: A leading candidate that inhibits the NEK7/NLRP3 inflammasome pathway. Initial clinical trials have shown promising results in reducing inflammatory biomarkers.
- Strategic Collaborations: Partnered with Biolexis Therapeutics, employing AI technologies to expedite drug discovery.
- Clinical Trials: Conducting multiple Phase II trials, including those for Alzheimer’s and inflammatory diseases.
- Funding and Growth: Secured significant investment through multiple funding rounds, enabling expansion of R&D capabilities and infrastructure.
Current Operations and Market Position
Halia Therapeutics operates from a modern headquarters in Lehi, Utah, equipped with state-of-the-art research facilities. The company is actively engaged in clinical trials across multiple continents, reflecting a strategic focus on both domestic and global markets. By targeting NEK7 and LRRK2, Halia aims to tackle diseases associated with neuroinflammation, offering potentially transformative treatments for conditions like Alzheimer's and Parkinson's.
Conclusion
Halia Therapeutics represents a promising entity in the realm of biotech. Its focus on innovative therapeutics for inflammatory and neurological conditions places it at the forefront of potential breakthrough treatments. As the company advances its clinical trials, it remains poised to make significant contributions to medical science and patient outcomes, potentially altering the landscape of treatment for chronic and complex diseases.